795 F. Supp. 2d 672 - Bower v. Johnson & Johnson’s Empirical Analysis
2011
Citation profile
1 federal appellate ·
Relationships
Applies 21 U.S.C. § 301 (Animal Drug Amendments of 1968) · 28 U.S.C. § 1332 (Class Action Fairness Act of 2005) · 28 U.S.C. § 1407
Relies on Anderson v. Liberty Lobby, Inc. · Celotex Corporation v. Catrett H · Matsushita Electric Industrial Co., Ltd. v. Zenith Radio Corporation · Neil v. Biggers · Wyeth v. Levine
Most-quoted passages
The sentences later courts lift from this opinion, ranked by how many decisions quote each — the parts of the opinion doing the work. These counts are smaller than the citation total above because most of the 1 citing decisions cite the case generally; a passage count includes only decisions quoting that exact language verbatim.
“In a product liability action against’ a manufacturer or seller, a product that is a drug is not defective or unreasonably dangerous, and the manufacturer or seller is not liable, if the drug was approved for safety and efficacy by the United States food and drug administration, and the drug and its labeling were in compliance with the United States food and drug administration’s approval at the time the drug left the control of the manufacturer or seller.”
1 later decision quote this exact passage · from the majority“and there being no dispute that Ortho Evra was subject to and successfully completed the FDA approval process,” that plaintiff’s products liability claims were precluded as a matter of Michigan law. Id. at 677 . Accordingly, the court in Bower held that the fact that the”
1 later decision quote this exact passage · from the majority
How this case has been treated — in progress
Whether each later court followed, distinguished, criticized, or overruled this decision. The treatment classification (task #35) runs highest-cited cases first and lights up here as it reaches this one.